<DOC>
	<DOCNO>NCT00977951</DOCNO>
	<brief_summary>The purpose study determine safety toleration intradermal avotermin ( Juvista ) , confirm accelerate heal investigate genomic expression profile</brief_summary>
	<brief_title>Genomic Changes Associated With Use Intradermal Avotermin ( Juvista ) Small Wounds Healthy Male Subjects</brief_title>
	<detailed_description>Subjects allocate two group . Group 1 schedule visit Day 0 , 1 , 3 4 group 2 schedule Day 0 , 1 , 5 6 . Follow-up post-trial safety assessment make Day 10-20 . On Day 0 subject receive total four 1cm incision wound ; two upper , inner aspect arm . Two area incision mark inner aspect upper arm anaesthetise intradermal injection Juvista placebo . One incision site arm receive dose 50ng/100μl Juvista incision site receive Placebo . Following injection full thickness 1cm incision make along marked site . On Day 1 subject re-injected dose Juvista placebo , 100μl wound margin ( 200μl per wound site ) . On Day 3 subject Group 1 re-dosed 200μl Juvista Placebo per site ( 100μl per linear cm approximate wound margin ) Arm 1 . These site excise elliptical excision . On Day 4 subject receive another dose Juvista placebo . Subjects group 2 receive treatment Arm 1 group 1 , except Day 5 6 . All wound monitor photograph two monthly interval course 6 month . At month 6 , incision site Arm 2 group excise . All excise wound snap frozen genomic analysis .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Cicatrix</mesh_term>
	<criteria>Healthy , Caucasian , male subject age 1845 year inclusive . Weight 60100 kg BMI within permitted range height use Quetelet 's index weight ( kg ) /height² ( ) . The permitted index 1828 . Nonsmokers , exsmokers smoke least 3 month prior screen . Subjects history evidence hypertrophic keloid scar tattoos previous scar area biopsied . AfroCaribbean subject exclude increased susceptibility hypertrophic keloid scarring . Subjects evidence past present clinically significant disease , particularly coagulation disorder , immunomediated condition skin disease allergy , clinically significant eczema . Subjects history clinically significant allergy , especially drug hypersensitivity lignocaine allergy surgical dressing use trial . Subjects clinically significant abnormality follow review pretrial laboratory data physical examination . Subjects take , take , certain prescribed investigational drug three week prior Day 0 particular topical systemic steroid , antiinflammatory anticoagulant drug . Certain drug exclude trial . These include OTC analgesic include paracetamol codeine , vitamin mineral supplement OTC cold remedy . Subjects drink 28 unit alcohol per week ( 1 unit = 1/2 pint beer ( 285mls ) 25ml spirit 1 glass wine ) . Subjects evidence drug abuse . Subjects know serum hepatitis carrier hepatitis B surface antigen hepatitis C antibody . Subjects previous vaccination Hepatitis B exclude per se . Subjects know serum hepatitis carrier hepatitis B core antibody show le 10 unit per litre AntiHBs . Subjects previously positive result test HIV antibody , admit belong high risk group . In opinion investigator , subject likely complete trial ever reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>Avotermin</keyword>
	<keyword>Juvista</keyword>
	<keyword>RN1001</keyword>
	<keyword>TGF beta 3</keyword>
</DOC>